Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TG TherapeuticsFRA:NKB2 +5.93%80 14-Day RSI is 57.67 as of Jul. 25, 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 80/100 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,424 Biotechnology companies, TG Therapeutics ranks worse than 88.48% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-25), TG Therapeutics's 14-Day RSI is 57.67.
The industry rank for TG Therapeutics's 14-Day RSI or its related term are showing as below:
FRA:NKB2's 14-Day RSI is ranked worse than 88.48% of 1424
companies
in the Biotechnology industry
Industry Median: 45.5
vs FRA:NKB2: 57.67
TG Therapeutics (FRA:NKB2) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
TG Therapeutics 14-Day RSI Related Terms
FRA:NKB2 vs HALO, KYMR, PCVX: 14-Day RSI Comparison
For the Biotechnology subindustry, TG Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (FRA:NKB2) has a 14-Day RSI of 57.67 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TG Therapeutics and its competitors. According to the industry distribution chart, TG Therapeutics ranks #1260 out of 1424 companies in the Biotechnology industry, placing it in the top 88.5%.
Is TG Therapeutics' 14-Day RSI too high?
TG Therapeutics' current 14-Day RSI is 57.67. The Biotechnology industry median 14-Day RSI is 45.50. TG Therapeutics' value of 57.67 is 26.7% above this industry median. Based on the distribution chart, TG Therapeutics ranks #1260 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TG Therapeutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' 14-Day RSI compare to HALO and KYMR?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #1260 out of 1424 companies for 14-Day RSI. This places TG Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 45.50. TG Therapeutics' value of 57.67 is 26.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.50, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TG Therapeutics's current 14-Day RSI of 57.67 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TG Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current 14-Day RSI is 57.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The current 14-Day RSI is 57.67 and 26.7% above the Biotechnology industry median of 45.50. TG Therapeutics' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current 14-Day RSI is 57.67 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
80GF Score
Get the complete analysis for FRA:NKB2
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
